These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 5632434)

  • 1. [Aldadiene and other metabolites in the blood and urine after rectal appliacation of spironolactone and injection of aldaliene-potassium].
    Wagner H; Weist F; Zicha L
    Arzneimittelforschung; 1967 Apr; 17(4):415-9. PubMed ID: 5632434
    [No Abstract]   [Full Text] [Related]  

  • 2. Spironolactone metabolism in man studied by gas chromatography-mass spectrometry.
    Karim A; Hribar J; Aksamit W; Doherty M; Chinn LJ
    Drug Metab Dispos; 1975; 3(6):467-78. PubMed ID: 1221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a simple fluorometric 11-hydroxycorticosteroids assay in the assessment of spironolactone-metabolite level in plasma and urine.
    Radó JP; Szende L; Takó J; Nagy O
    Endokrinologie; 1974 Nov; 64(1):22-32. PubMed ID: 4466654
    [No Abstract]   [Full Text] [Related]  

  • 4. Disposition of tritium-labeled spirolactones in the dog.
    Sadée W; Riegelman S; Jones SC
    J Pharm Sci; 1972 Jul; 61(7):1132-5. PubMed ID: 5044816
    [No Abstract]   [Full Text] [Related]  

  • 5. [Comparative study of relative biovailability of several spironolactone formulations in a steady-state test (author's transl)].
    Rosenthal J; Jaeger H; Specker M
    Arzneimittelforschung; 1979; 29(9):1428-32. PubMed ID: 583254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of spironolactone on diuresis and urine sodium and potassium excretion in healthy dogs.
    Jeunesse E; Woehrle F; Schneider M; Lefebvre HP
    J Vet Cardiol; 2007 Nov; 9(2):63-8. PubMed ID: 18024236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.
    Sadée W; Dagcioglu M; Schröder R
    J Pharmacol Exp Ther; 1973 Jun; 185(3):686-95. PubMed ID: 4712657
    [No Abstract]   [Full Text] [Related]  

  • 8. Conversion of spironolactone to canrenone and disposition kinetics of spironolactone and canrenoate-potassium in rats.
    Sadée W; Abshagen U; Finn C; Rietbrock N
    Naunyn Schmiedebergs Arch Pharmacol; 1974; 283(3):303-18. PubMed ID: 4276758
    [No Abstract]   [Full Text] [Related]  

  • 9. [Positive-inotropic heart effect of aldadiene-potassium (Aldactone pro injections)].
    Schröder R; Schüren KP; Biamino G; Meyer V; Sadée W
    Klin Wochenschr; 1971 Oct; 49(19):1093-6. PubMed ID: 5115330
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.
    Dasgupta A; Tso G; Wells A
    Ther Drug Monit; 2008 Dec; 30(6):744-7. PubMed ID: 18824952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Results of treatment of the chronic general alveolar hypoventilation with aldadiene potassium].
    Ferlinz R; Schroers E; Stadeler HJ
    Med Welt; 1969 Aug; 32():1751-4. PubMed ID: 5801063
    [No Abstract]   [Full Text] [Related]  

  • 12. Identification of spironolactone metabolites in plasma and target organs of guinea pigs.
    Los LE; Coddington AB; Ramjit HG; Colby HD
    Drug Metab Dispos; 1993; 21(6):1086-90. PubMed ID: 7905388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of entekohepatic circulation on the pharmacokinetics of spironolactone in man.
    Abshagen U; von Grodzicki U; Hirschberger U; Rennekamp H
    Naunyn Schmiedebergs Arch Pharmacol; 1977 Nov; 300(3):281-7. PubMed ID: 600314
    [No Abstract]   [Full Text] [Related]  

  • 14. Development and validation of an HPLC method for the determination of spironolactone and its metabolites in paediatric plasma samples.
    Sandall JM; Millership JS; Collier PS; McElnay JC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jul; 839(1-2):36-44. PubMed ID: 16510319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of metabolites--a new approach to bioequivalence studies of spironolactone formulations.
    Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V; Martens H
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):334-40. PubMed ID: 9266289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot randomised double-blind controlled trial of high-dose spironolactone in critically ill patients receiving a frusemide infusion.
    Apte Y; Bellomo R; Warrillow S; Goldsmith D; Gillies M; McGain F
    Crit Care Resusc; 2008 Dec; 10(4):306-11. PubMed ID: 19049481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gas chromatographic determination of levels of aldadiene in human plasma and urine following therapeutic doses of spironolactone.
    Chamberlain J
    J Chromatogr; 1971 Mar; 55(2):249-53. PubMed ID: 5547796
    [No Abstract]   [Full Text] [Related]  

  • 18. Investigation on the bioequivalence of 2 oral preparations containing spironolactone and furosemide.
    Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V
    Int J Clin Pharmacol Ther; 1998 Apr; 36(4):231-8. PubMed ID: 9587051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bioavailability studies of two spironolactone-preparations (author's transl)].
    Vergin H; Nuss U; Schwarzländer F; Strobel K; Weigand W; Hitzenberger G
    Arzneimittelforschung; 1981; 31(9):1498-503. PubMed ID: 7197963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma cortisol after spironolactone.
    Wood LC; Richards R; Ingbar SH
    N Engl J Med; 1970 May; 282(21):1214-5. PubMed ID: 5445892
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.